OSF Opens Enrollment in Two-Drug Trial for EGFR-Mutated Lung Cancer

URL has been copied successfully!

OSF HealthCare Cancer Institute is enrolling adults with a specific form of advanced lung cancer in a study testing a two-drug combination as an initial treatment. The trial offers eligible patients in central Illinois access to an experimental approach, but whether the combination improves disease control remains to be determined.

The health system announced the local study opening in a November 6 update. The international Phase 2/3 trial, known as M25-287, is studying telisotuzumab adizutecan, also called ABBV-400, together with osimertinib.

Trial targets lung cancers with EGFR mutations

The study focuses on adults with advanced non-squamous non-small cell lung cancer carrying specific mutations in EGFR, a gene that can help drive cancer growth.

Osimertinib is an established EGFR-targeted medicine. The other drug is an investigational antibody-drug conjugate aimed at c-MET, a protein on cells. Antibody-drug conjugates are designed to recognize a target and deliver cancer medicine to cells.

Researchers are testing whether combining treatments that work through different mechanisms can improve control of the disease when used at the beginning of care for advanced cancer.

First-line treatment means the initial treatment choice

Targeted medicines have changed care for some lung cancers, but tumors can eventually become resistant. The trial examines whether adding the experimental drug to an established targeted treatment earlier in care could help address that problem.

The study opening is an enrollment announcement, not a report of successful treatment results. The combination remains under investigation.

Jun Zhang, OSF’s vice president of oncology research, is the principal investigator at the Cancer Institute. OSF’s participation is part of a broader multicenter research effort.

Eligibility depends on more than a diagnosis

Patients must have the specified cancer type and EGFR mutations and meet additional study requirements. OSF directs interested patients to speak with their cancer-care team or call its research team at 844-673-4467.

The trial is registered under identifier NCT07005102. A patient’s oncology team can help assess whether a clinical study fits their diagnosis, treatment history and other medical needs.

JBizNews Desk | Health

© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.

Share this story:
Share on Facebook
Share by Email
X (Twitter)
Follow Me
Tweet
Whatsapp
LinkedIn
Copy link